Cargando…

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer

DNA damage responses contribute to cisplatin resistance; however, therapeutic strategies to overcome cisplatin resistance have not yet been established. Here, we demonstrate that inhibition of ATR-Chk1 pathway with the potent inhibitor WYC0209 sensitizes bladder cancer cells to cisplatin. In the cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ching-Chia, Yang, Juan-Cheng, Lu, Mei-Chin, Lee, Chia-Lin, Peng, Chieh-Yu, Hsu, Wei-Yu, Dai, Yun-Hao, Chang, Fang-Rong, Zhang, Da-Yong, Wu, Wen-Jeng, Wu, Yang-Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811508/ https://www.ncbi.nlm.nih.gov/pubmed/26657501

Ejemplares similares

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
por: Chen, Sansan, et al.
Publicado: (2016)

7-Ketocholesterol induces ATM/ATR, Chk1/Chk2, PI3K/Akt signalings, cytotoxicity and IL-8 production in endothelial cells
por: Chang, Mei-Chi, et al.
Publicado: (2016)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling
por: Gan, Yu, et al.
Publicado: (2017)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair
por: Xu, Caihua, et al.
Publicado: (2021)

Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation
por: Shen, Tao, et al.
Publicado: (2018)

Prognostic Impact of Thrombospodin-2 (THBS2) Overexpression on Patients with Urothelial Carcinomas of Upper Urinary Tracts and Bladders
por: Chang, I-Wei, et al.
Publicado: (2016)

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
por: van den Tempel, Nathalie, et al.
Publicado: (2018)

The Predictive Value of Systemic Immune-Inflammation Index on Bladder Recurrence on Upper Tract Urothelial Carcinoma Outcomes after Radical Nephroureterectomy
por: Chien, Tsu-Ming, et al.
Publicado: (2021)

Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1
por: Zhou, Zhaohui, et al.
Publicado: (2022)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
por: Ahmed, Salman, et al.
Publicado: (2022)

Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
por: Su, Yu-Li, et al.
Publicado: (2023)

Differentiation of Urothelial Carcinoma and Normal Bladder Tissues by Means of Fiber-Based ATR IR Spectroscopy
por: Bandzevičiūtė, Rimantė, et al.
Publicado: (2023)

ASPM promotes ATR-CHK1 activation and stabilizes stalled replication forks in response to replication stress
por: Wu, Xingxuan, et al.
Publicado: (2022)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
por: Ma, Hanhui, et al.
Publicado: (2013)

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors()
por: Job, Albert, et al.
Publicado: (2018)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition
por: Sundararajan, Vignesh, et al.
Publicado: (2022)

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
por: Nie, Sipei, et al.
Publicado: (2021)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder
por: Lee, Yi-Ying, et al.
Publicado: (2016)

CTP sensing and Mec1(ATR)-Rad53(CHK1/CHK2) mediate a two-layered response to inhibition of glutamine metabolism
por: Ajazi, Arta, et al.
Publicado: (2022)

Multiple ATR-Chk1 Pathway Proteins Preferentially Associate with Checkpoint-Inducing DNA Substrates
por: Yilmaz, Seçil, et al.
Publicado: (2011)

Correction for The nucleolus stress response is coupled to an ATR-Chk1–mediated G2 arrest
Publicado: (2013)

Critical role of SMG7 in activation of the ATR-CHK1 axis in response to genotoxic stress
por: Ho, Kathleen, et al.
Publicado: (2021)

PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors
por: Göder, Anja, et al.
Publicado: (2023)

Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth via ROS‐mediated apoptosis and ATM/ATR–Chk1/Chk2‐regulated cell cycle arrest
por: Neumann, Jennifer, et al.
Publicado: (2015)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer
por: Huang, Weicai, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors
por: Zong, Chunyan, et al.
Publicado: (2023)

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
por: Chen, Jinbo, et al.
Publicado: (2016)

Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts
por: Yang, Chia-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_05kmoeg7tir12v1q235hgc2rvm